Cameron Demond Thomas

Cameron Demond Thomas

Auto-generated profile, based on publicly available information

Cameron Demond Thomas

Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy University of Florida Gainesville Florida USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
JDJulio D. Duarte
Julio D. Duarte
CTCameron D. Thomas
Cameron D. Thomas
CLCraig R. Lee
Craig R. Lee
RHRachel Huddart
Rachel Huddart
Jose AgundezJose Agundez
Jose Agundez
JLJasmine A. Luzum
Jasmine A. Luzum
Beta‐blockers are widely used medications for a variety of indications, including heart failure, myocardial infarction, cardiac arrhythmias, and hypertension. Genetic variability in pharmacokinetic (e.g., CYP2D6) and pharmacodynamic (e.g., ADRB1, ADRB2, ADRA2C, GRK4, GRK5) genes have been studied in relation to beta‐blocker exposure and response. We searched and summarized the strength of the evidence linking beta‐blocker exposure and response with the six genes listed above. The level of evidence was high for associations between CYP2D6 genetic variation and both metoprolol exposure and heart rate response. Evidence indicates that CYP2D6 poor metabolizers experience clinically significant greater exposure and lower heart rate in response to metoprolol compared with those who are not poor metabolizers. Therefore, we provide therapeutic recommendations regarding genetically predicted CYP2D6 metabolizer status and metoprolol therapy. However, there was insufficient evidence to make therapeutic recommendations for CYP2D6 and other beta‐blockers or for any beta‐blocker and the other five genes evaluated (updates at www.cpicpgx.org).

9 September 2020 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Closed access
CTCameron D. Thomas
Cameron D. Thomas
JJJulie A. Johnson
Julie A. Johnson
β-blockers are among the most widely prescribed of all drugs, used for treatment of a large number of cardiovascular diseases. Herein we evaluate literature pertaining to pharmacogenetics of β-bloc...

13 January 2023 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
CTCameron D. Thomas
Cameron D. Thomas
AWAlexis K. Williams
Alexis K. Williams
CLCraig R. Lee
Craig R. Lee
LCLarisa H. Cavallari
Larisa H. Cavallari

2 May 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
CTCameron D. Thomas
Cameron D. Thomas
FFFrancesco Franchi
Francesco Franchi
EKEllen C. Keeley
Ellen C. Keeley
JRJoseph S. Rossi
Joseph S. Rossi
MWMarshall Winget
Marshall Winget
LCLarisa H. Cavallari
Larisa H. Cavallari
The Age, Body mass index, Chronic kidney disease, Diabetes mellitus, and CYP2C19 GENEtic variants (ABCD‐GENE) score was developed to identify patients at risk for diminished antiplatelet effects with clopidogrel after percutaneous coronary intervention (PCI). The objective of this study was to validate the ability of the ABCD‐GENE score to predict the risk for atherothrombotic events in a diverse, real‐world population of clopidogrel‐treated patients who underwent PCI and received clinical CYP2C19 genotyping to guide antiplatelet therapy. A total of 2,341 adult patients who underwent PCI, were genotyped for CYP2C19, and received treatment with clopidogrel across four institutions were included (mean age 64 ± 12 years, 35% women, and 20% Black). The primary outcome was major atherothrombotic events, defined as the composite of all‐cause death, myocardial infarction, ischemic stroke, stent thrombosis, or revascularization for unstable angina within 12 months following PCI. Major adverse cardiovascular events (MACE), defined as the composite of cardiovascular death, myocardial infarction, ischemic stroke, or stent thrombosis, was assessed as the secondary outcome. Outcomes were compared between patients with an ABCD‐GENE score ≥ 10 vs. < 10. The risk of major atherothrombotic events was higher in patients with an ABCD‐GENE score ≥ 10 (n = 505) vs. < 10 (n = 1,836; 24.6 vs. 14.7 events per 100 patient‐years, adjusted hazard ratio (HR) 1.66, 95% confidence interval (CI), 1.23–2.25, P < 0.001). The risk for MACE was also higher among patients with a score ≥ 10 vs. < 10 (16.7 vs. 10.1 events per 100 patient‐years, adjusted HR 1.59, 95% CI 1.11–2.30, P = 0.013). Our diverse, real‐world data demonstrate diminished clopidogrel effectiveness in post‐PCI patients with an ABCD‐GENE score ≥ 10.

8 April 2024 in JACC
Verified
Journal Article
Closed access
CTCameron D. Thomas
Cameron D. Thomas
FFFrancesco Franchi
Francesco Franchi
JRJoseph S. Rossi
Joseph S. Rossi
EKEllen C. Keeley
Ellen C. Keeley
RAR. David Anderson
R. David Anderson
LCLarisa H. Cavallari
Larisa H. Cavallari

4 August 2022 in Clinical and Translational Science
Verified
Journal Article
Open access
LCLarisa H. Cavallari
Larisa H. Cavallari
ECEmily Cicali
Emily Cicali
KWKristin Wiisanen
Kristin Wiisanen
RFRoger B. Fillingim
Roger B. Fillingim
HCHrishikesh Chakraborty
Hrishikesh Chakraborty
FNFor The Ignite Pragmatic Trials Network
For The Ignite Pragmatic Trials Network
Opioid prescribing for postoperative pain management is challenging because of inter‐patient variability in opioid response and concern about opioid addiction. Tramadol, hydrocodone, and codeine depend on the cytochrome P450 2D6 (CYP2D6) enzyme for formation of highly potent metabolites. Individuals with reduced or absent CYP2D6 activity (i.e., intermediate metabolizers [IMs] or poor metabolizers [PMs], respectively) have lower concentrations of potent opioid metabolites and potentially inadequate pain control. The primary objective of this prospective, multicenter, randomized pragmatic trial is to determine the effect of postoperative CYP2D6‐guided opioid prescribing on pain control and opioid usage. Up to 2020 participants, age ≥8 years, scheduled to undergo a surgical procedure will be enrolled and randomized to immediate pharmacogenetic testing with clinical decision support (CDS) for CYP2D6 phenotype‐guided postoperative pain management (intervention arm) or delayed testing without CDS (control arm). CDS is provided through medical record alerts and/or a pharmacist consult note. For IMs and PM in the intervention arm, CDS includes recommendations to avoid hydrocodone, tramadol, and codeine. Patient‐reported pain‐related outcomes are collected 10 days and 1, 3, and 6 months after surgery. The primary outcome, a composite of pain intensity and opioid usage at 10 days postsurgery, will be compared in the subgroup of IMs and PMs in the intervention (n = 152) versus the control (n = 152) arm. Secondary end points include prescription pain medication misuse scores and opioid persistence at 6 months. This trial will provide data on the clinical utility of CYP2D6 phenotype‐guided opioid selection for improving postoperative pain control and reducing opioid‐related risks.